May 31, 2022
Sandra Hamilton, Founder of Cure-Cancer @UCL Institute
We have the honor of speaking again today with Sandra Hamilton of the "Cure-Cancer Foundation" (CCF) which supports the University College London, Non-Hodgkin's Lymphoma Cancer Research Division. She will discuss how the financial toll of this disease has affected her and her family, and what she has found helpful in this journey. She is joined today by her friend and colleague Julia Selt, the Coordinator at CCF.
This week we are talking about the cost factors of having a diagnosis of Non-Hodgkin's Lymphoma. "Non-Hodgkin's lymphoma (NHL) is not a single disease entity but covers a complex group of different types of malignancy. They differ in the cells affected, their course and the structures they form in the lymph glands. The unifying feature of the lymphomas as a whole is that they are all cancerous growths of lymphocytes. These are cells of the immune system which are produced from bone marrow and are located within the lymph glands. Lymphocytes are designed to fight infection by either directly producing or helping to produce antibodies. (credits: Office of Home Economics /UK https://bit.ly/3t7sIn7)
With the incidence of this cancer increasing (4% /year since 1950 ) this is a cancer that is wreaking havoc on the over 65 year old population not only in the health aspects but also the financial pains it can bring as well.